| Drug General Information |
| Drug ID |
D0N1FS
|
| Former ID |
DNC000544
|
| Drug Name |
Diacerein
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Phase 4 |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C19H12O8
|
| Canonical SMILES |
CC(=O)OC1=CC=CC2=C1C(=O)C3=C(C=C(C=C3C2=O)C(=O)O)OC(=O)<br />C
|
| InChI |
1S/C19H12O8/c1-8(20)26-13-5-3-4-11-15(13)18(23)16-12(17(11)22)6-10(19(24)25)7-14(16)27-9(2)21/h3-7H,1-2H3,(H,24,25)
|
| InChIKey |
TYNLGDBUJLVSMA-UHFFFAOYSA-N
|
| CAS Number |
CAS 13739-02-1
|
| PubChem Compound ID |
|
| PubChem Substance ID |
855680, 4363810, 8169045, 11341914, 11362097, 11364807, 11367369, 11369931, 11372073, 11374729, 11378098, 11484481, 11487499, 11488639, 11490752, 11492850, 11495690, 12012675, 14901773, 24894281, 26612251, 26680442, 26746957, 28325764, 29293111, 47942826, 49830871, 49870698, 50100992, 51091608, 57310202, 76715691, 80030301, 81041119, 85279713, 91011503, 103220500, 104171387, 104296775, 117575544, 117689433, 124638102, 124883601, 124883602, 125325747, 125340536, 126592381, 126666939, 129332407, 131298280
|
| SuperDrug ATC ID |
M01AX21
|
| SuperDrug CAS ID |
cas=013739021
|
| Target and Pathway |
| Target(s) |
Interleukin-1 beta |
Target Info |
Inhibitor |
[2]
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
NF-kappa B signaling pathway
|
|
Apoptosis
|
|
Osteoclast differentiation
|
|
Toll-like receptor signaling pathway
|
|
NOD-like receptor signaling pathway
|
|
Cytosolic DNA-sensing pathway
|
|
Hematopoietic cell lineage
|
|
TNF signaling pathway
|
|
Inflammatory mediator regulation of TRP channels
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Type I diabetes mellitus
|
|
Alzheimer's disease
|
|
Prion diseases
|
|
Salmonella infection
|
|
Pertussis
|
|
Legionellosis
|
|
Leishmaniasis
|
|
Chagas disease (American trypanosomiasis)
|
|
African trypanosomiasis
|
|
Malaria
|
|
Amoebiasis
|
|
Tuberculosis
|
|
Measles
|
|
Influenza A
|
|
Herpes simplex infection
|
|
Inflammatory bowel disease (IBD)
|
|
Rheumatoid arthritis
|
|
Graft-versus-host disease
|
|
NetPath Pathway
|
Leptin Signaling Pathway
|
|
IL5 Signaling Pathway
|
|
IL1 Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
IL3 Signaling Pathway
|
|
TGF_beta_Receptor Signaling Pathway
|
|
Wnt Signaling Pathway
|
|
TCR Signaling Pathway
|
|
TNFalpha Signaling Pathway
|
|
Pathway Interaction Database
|
IL27-mediated signaling events
|
|
IL12-mediated signaling events
|
|
IL1-mediated signaling events
|
|
IFN-gamma pathway
|
|
IL23-mediated signaling events
|
|
Cellular roles of Anthrax toxin
|
|
Reactome
|
Interleukin-1 signaling
|
|
Interleukin-1 processing
|
|
CLEC7A/inflammasome pathway
|
|
WikiPathways
|
Toll-like receptor signaling pathway
|
|
Monoamine Transport
|
|
SIDS Susceptibility Pathways
|
|
TCR Signaling Pathway
|
|
Type II interferon signaling (IFNG)
|
|
Senescence and Autophagy in Cancer
|
|
Cytokines and Inflammatory Response
|
|
MAPK Signaling Pathway
|
|
Myometrial Relaxation and Contraction Pathways
|
|
Aryl Hydrocarbon Receptor Pathway
|
|
IL1 and megakaryotyces in obesity
|
|
Hematopoietic Stem Cell Differentiation
|
|
Spinal Cord Injury
|
|
Allograft Rejection
|
|
Alzheimers Disease
|
|
Leptin signaling pathway
|
|
IL-1 signaling pathway
|
|
Interleukin-1 signaling
|
|
Folate Metabolism
|
|
Vitamin B12 Metabolism
|
|
Selenium Micronutrient Network
|
|
Serotonin Transporter Activity
|
|
Regulation of toll-like receptor signaling pathway
|
|
NOD pathway
|
| References |
| REF 1 | ClinicalTrials.gov (NCT00685542) Effect of Diacerein on Hand Osteoarthritis. U.S. National Institutes of Health. |
|---|
| REF 2 | Non-surgical treatment of osteoarthritis of large joints - new aspects. Wien Med Wochenschr. 2009;159(3-4):76-86. |
|---|
